Lenacapavir – Latest stories from Nourish

a { color: #880000 !important; background: #ffeeee !important; } Latest News from NourishThe Nourish Mission (formerly OneSub)Get answers to today's big questionsWhy is Lenacapavir in the news at the moment?

Lenacapavir’s in the news as Africa’s first country gets its first twice-yearly HIV prevention shot, a game-changer for global HIV efforts.

Stories involving Lenacapavir

US Cuts HIV Aid to South Africa

The US has suspended most funding for South Africa's HIV programs, impacting thousands of health workers and clinics. Despite a new bridge plan, tensions remain high amid strained diplomatic relations and ongoing political disputes. The move threatens progress in HIV prevention and treatment in the region.

New Long-Acting HIV Prevention Approved in UK and Zimbabwe

England is set to approve cabotegravir, a two-month injectable HIV prevention shot, expanding options for those unable to take daily pills. Zimbabwe will roll out lenacapavir, a twice-yearly prophylactic, amid debates over cost and safety. Both developments mark significant advances in HIV prevention efforts.

Long-Acting HIV Prevention Shot Expands in Africa

Gilead Sciences' long-acting HIV injection, lenacapavir, is set for rollout in Africa, starting with Eswatini, as part of a US-led initiative. The drug offers hope for improved adherence and prevention, but high costs and regulatory hurdles remain. Namibia is among potential future recipients.